Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability

References

• KohroTYamazakiTSatoHTrends in antidiabetic prescription patterns in Japan from 2005 to 2011Int Heart J201354293 9723676369
   PubMed Web of Science ®Google Scholar
• TurnerLWNarteyDStaffordRSSinghSAlexanderGCAmbulatory treatment of type 2 diabetes in the US, 1997–2012Diabetes Care2014374985 99224198301
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2014Diabetes Care201437Suppl 1S14 S8024357209
   PubMed Web of Science ®Google Scholar
• ItoHIshidaHTakeuchiYLong-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitusNutr Metab2010201783
   Google Scholar
• ItoHTakeuchiYIshidaHHigh frequencies of diabetic micro-and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuriaNephrol Dial Transplant20102541161 116719892756
   PubMed Web of Science ®Google Scholar
• ItoHOshikiriKMifuneMThe usefulness of the revised classification for chronic kidney disease by the KDIGO for determining the frequency of diabetic micro- and macroangiopathies in Japanese patients with type 2 diabetes mellitusJ Diabetes Complications2012264286 29022621778
   PubMed Web of Science ®Google Scholar
• National Kidney FoundationKDOQI clinical practice guideline for diabetes and CKD: 2012 updateAm J Kidney Dis2012605850 88623067652
   PubMed Web of Science ®Google Scholar
• TuttleKRBakrisGLBilousRWDiabetic kidney disease: a report from an ADA consensus conferenceDiabetes Care201437102864 288325249672
   PubMed Web of Science ®Google Scholar
• Japan Diabetes SocietyTreatment Guide for Diabetes 2012–2013TokyoBunkodo2012
   Google Scholar
• ItoHMifuneMMatsuyamaEVildagliptin is effective for glycemic control in diabetic patients undergoing either hemodialysis or peritoneal dialysisDiabetes Ther201342321 32923801219
   PubMed Web of Science ®Google Scholar
• AschnerPKipnesMSLuncefordJKSitagliptin Study 021 GroupEffect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetesDiabetes Care200629122632 263717130196
   PubMed Web of Science ®Google Scholar
• Pi-SunyerFXSchweizerAMillsDDejagerSEfficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetesDiabetes Res Clin Pract2007761132 13817223217
   PubMed Web of Science ®Google Scholar
• DeFronzoRAFleckPRWilsonCAMekkiQAlogliptin Study 010 GroupEfficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled studyDiabetes Care200831122315 231718809631
   PubMed Web of Science ®Google Scholar
• Del PratoSBarnettAHHuismanHNeubacherDWoerleHJDugiKAEffect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trialDiabetes Obes Metab2011133258 26721205122
   PubMed Web of Science ®Google Scholar
• KadowakiTKondoKEfficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitusDiabetes Obes Metab2013159810 81823464664
   PubMed Web of Science ®Google Scholar
• RosenstockJAguilar-SalinasCKleinECV181-011 Study InvestigatorsEffect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetesCurr Med Res Opin200925102401 241119650754
   PubMed Web of Science ®Google Scholar
• KakuKEfficacy and safety of long-term monotherapy with anagliptin in Japanese patients with type 2 diabetes – a multi-centre. Randomised, open-label, parallel-group study (administered before meals vs after meals)Jpn Pharmacol Ther20124010733 744 Japanese [Abstract in English]
   Google Scholar
• Sanwa Kagaku Kenkyusho Co, Ltd 2015 Available from: http://med.skk-net.com/resources/show?colum=refference_files&field=doc_mng&num=1&thread_id=d2a5fafb-796e-4409-9986-2d4ba2f5b2adAccessed January 25, 2015 Japanese
   Google Scholar
• KakuKDose-ranging study of anagliptin in Japanese patients with type 2 diabetes – a multi-centre, randomized, placebo-controlled, double-blind, parallel-group studyJpn Pharmacol Ther20124011944 973 Japanese [Abstract in English]
   Google Scholar
• KakuKEfficacy and safety of anagliptin in Japanese patients with type 2 diabetes – a multi-centre, randomized, placebo-controlled, double-blind, parallel-group studyJpn Pharmacol Ther20124011985 995 Japanese [Abstract in English]
   Google Scholar
• KakuKEffects of anagliptin on the new goal achievement rates for glycemic control in Japanese patients with type 2 diabetesJpn Pharmacol Ther20124110965 974 Japanese [Abstract in English]
   Google Scholar
• KakuKEfficacy and safety of anagliptin add-on therapy in Japanese patients with type 2 diabetesJpn Pharmacol Ther2012409745 770 Japanese [Abstract in English]
   Google Scholar
• MannucciEOgnibeneACremascoFEffect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjectsDiabetes Care2001243489 49411289473
   PubMed Web of Science ®Google Scholar
• LindsayJRDuffyNAMcKillopAMInhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetesDiabet Med2005225654 65715842525
   PubMed Web of Science ®Google Scholar
• QualmannCNauckMAHolstJJOrskovCCreutzfeldtWGlucagon-like peptide 1 (7–36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose)Scand J Gastroenterol1995309892 8968578189
   PubMed Web of Science ®Google Scholar
• KimKKakuKDrug interaction between anagliptin, a novel dipeptidyl peptidase-4 inhibitor, and miglitol, an α-glucosidase inhibitor, in Japanese patients with type 2 diabetesJpn Pharmacol Ther20124010871 881 Japanese [Abstract in English]
   Google Scholar
• KimKKakuKDrug interaction between anagliptin, a novel α-glucosidase inhibitor, and metformin in Japanese patients with type 2 diabetesJpn Pharmacol Ther20124010883 894 Japanese [Abstract in English]
   Google Scholar
• HermansenKKipnesMLuoESitagliptin Study 035 GroupEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes Obes Metab200795733 74517593236
   PubMed Web of Science ®Google Scholar
• UchinoHKakuKA novel dipeptidyl peptidase-4 inhibitor, anagliptin, improved the daily blood glucose profileJpn Pharmacol Ther20124010859 869 Japanese [Abstract in English]
   Google Scholar
• SoneHTanakaSTanakaSJapan Diabetes Complications Study GroupSerum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS)J Clin Endocrinol Metab201196113448 345621865372
   PubMed Web of Science ®Google Scholar
• KakuKEffects of anagliptin on serum lipids in Japanese patients with type 2 diabetes – a pooled analysis of long-term therapy with anagliptinJpn Pharmacol Ther2012409771 784 Japanese [Abstract in English]
   Google Scholar
• MonamiMAhrénBDicembriniIMannucciEDipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trialsDiabetes Obes Metab2013152112 12022925682
   PubMed Web of Science ®Google Scholar
• ErvinnaNMitaTYasunariEAnagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient miceEndocrinology201315431260 127023337530
   PubMed Web of Science ®Google Scholar
• KakudaHKobayashiJKakudaMYamakawaJTakekoshiNThe effect of anagliptin treatment on glucose metabolism and lipid metabolism, and oxidative stress in fasting and postprandial states using a test meal in Japanese men with type 2 diabetesEndocrine2014
   Web of Science ®Google Scholar
• ImaiCHarazakiTInoueSMochizukiKGodaTInhibition of postprandial hyperglycemia by either an insulin-dependent or - independent drug reduces the expression of genes related to inflammation in peripheral leukocytes of OLETF ratsBiosci Biotechnol Biochem201377112305 230824200798
   PubMed Web of Science ®Google Scholar
• MimuraSAndoTIshiguroKDipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitisScand J Gastroenterol201348101152 115924047394
   PubMed Web of Science ®Google Scholar
• Sanwa Kagaku Kenkyusho Co, Ltd 2015 Available from: http://med.skk-net.com/information/download/578/file1Accessed January 25, 2015 Japanese
   Google Scholar
• HamasakiHYanaiHThe development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptinInt J Cardiol20131683e10623972359
   PubMed Web of Science ®Google Scholar
• BrownNJByiersSCarrDMaldonadoMWarnerBADipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedemaHypertension2009543516 52319581505
   PubMed Web of Science ®Google Scholar
• SciricaBMBhattDLBraunwaldESAVOR-TIMI 53 Steering Committee and InvestigatorsSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med2013369141317 132623992601
   PubMed Web of Science ®Google Scholar
• WuSHopperISkibaMKrumHDipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participantsCardiovasc Ther2014324147 15824750644
   PubMed Web of Science ®Google Scholar
• WhiteWBCannonCPHellerSREXAMINE InvestigatorsAlogliptin after acute coronary syndrome in patients with type 2 diabetesN Engl J Med2013369141327 133523992602
   PubMed Web of Science ®Google Scholar
• WhiteWBPratleyRFleckPCardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitusDiabetes Obes Metab2013157668 67323489301
   PubMed Web of Science ®Google Scholar
• ItoHAbeMAntokuSComparison of the antidiabetic effects of linagliptin among groups with a normal renal function and a mild or severe renal impairment – retrospective observation study of Japanese patients with type 2 diabetes mellitusExpert Opin Pharmacother2015163289 29625529857
   PubMed Web of Science ®Google Scholar
• AndoSTsugamiESuzukiSRecent trend in the prescription rates of antidiabetic agents in our facilityJournal of Japan Diabetes Society201356Suppl 1S164
   Google Scholar